Inovio Pharmaceuticals Investors May File Securities Fraud Lawsuit Amid Manufacturing Deficiencies

Inovio Pharmaceuticals shareholders who lost money may lead a securities fraud class action lawsuit against the company. The complaint alleges that Inovio failed to disclose manufacturing issues, unrealistic regulatory and commercial prospects, and overstated positive statements about its business and operations. Investors with substantial losses can contact the Law Offices of Howard G. Smith before April 7, 2026, to participate in the ongoing lawsuit.